Home Cart Sign in  
Chemical Structure| 188791-09-5 Chemical Structure| 188791-09-5

Structure of JTE-607
CAS No.: 188791-09-5

Chemical Structure| 188791-09-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

JTE-607 is a small molecule that was developed as an inflammatory cytokine inhibitor, which directly targets CPSF3 and inhibits pre-mRNA processing.

Synonyms: JTE-607 Dihydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of JTE-607

CAS No. :188791-09-5
Formula : C25H33Cl4N3O5
M.W : 597.36
SMILES Code : O=C(OCC)[C@@H](NC(C1=CC(Cl)=C(OCCN2CCN(C)CC2)C(Cl)=C1O)=O)CC3=CC=CC=C3.[H]Cl.[H]Cl
Synonyms :
JTE-607 Dihydrochloride
MDL No. :MFCD07363998
InChI Key :JUJAUEQJEWIWCQ-FJSYBICCSA-N
Pubchem ID :9938544

Safety of JTE-607

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of JTE-607

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
U937MP cells 1 μM 7 hours Observed widespread gene expression changes, with more downregulated genes than upregulated genes, and more sensitive than U937 cells Nat Commun. 2023 Aug 1;14(1):4480
U937 cells 1 μM 7 hours Observed widespread gene expression changes, with more downregulated genes than upregulated genes Nat Commun. 2023 Aug 1;14(1):4480
HepG2 cells 1 μM or 10 μM 8 hours Observed widespread gene expression changes, with more downregulated genes than upregulated genes, and more sensitive than HeLa cells Nat Commun. 2023 Aug 1;14(1):4480
HeLa cells 1 μM or 10 μM 8 hours Observed widespread gene expression changes, with more downregulated genes than upregulated genes Nat Commun. 2023 Aug 1;14(1):4480
NOMO-1 AML cells 1 or 10 μM 1.5, 4, or 24 hours To evaluate the effect of JTE-607 on apoptosis in AML cells, results showed increased apoptosis Nat Chem Biol. 2020 Jan;16(1):50-59
THP-1 AML cells 1 μM 72 hours To evaluate the effect of JTE-607 on AML cells, results showed inhibition of cell growth Nat Chem Biol. 2020 Jan;16(1):50-59
A-673 Ewing’s sarcoma cells 0.4 μM 72 hours To evaluate the effect of JTE-607 on Ewing’s sarcoma cells, results showed inhibition of cell growth Nat Chem Biol. 2020 Jan;16(1):50-59
Non-transformed pancreatic epithelial cells 130.4 μM (HPNE), 60.11 μM (HPDE) 72 hours JTE-607 has no significant effect on non-transformed pancreatic cells RNA. 2024 Feb 16;30(3):281-297
Pancreatic ductal adenocarcinoma cells (PDAC) 2.163 μM (most sensitive in Panc1) 72 hours JTE-607 selectively inhibits PDAC cell proliferation but has no effect on non-transformed pancreatic cells RNA. 2024 Feb 16;30(3):281-297

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice Intracranial transplantation of GSC3565 cells Direct delivery via osmotic minipump 7.143 μg/day/mouse Continuous administration JTE-607 suppressed tumor growth and prolonged mouse survival Cell Discov. 2024 Mar 19;10(1):32
Nude mice MOLM-13 AML xenograft model Subcutaneous injection 20 mg/kg Twice daily, continuous treatment To evaluate the anti-tumor effect of JTE-607 in AML xenograft model, results showed tumor stasis Nat Chem Biol. 2020 Jan;16(1):50-59

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.67mL

0.33mL

0.17mL

8.37mL

1.67mL

0.84mL

16.74mL

3.35mL

1.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories